More about

Hypertriglyceridemia

News
September 21, 2024
3 min read
Save

Annual CMHC: Honoring the life and legacy of CMHC co-chair George L. Bakris, MD

Annual CMHC: Honoring the life and legacy of CMHC co-chair George L. Bakris, MD

For nearly 2 decades, George L. Bakris, MD, was a pillar of the Cardiometabolic Health Congress, sharing his expertise, passion and unwavering dedication to advancing cardiometabolic health.

Clinical Guidance
Lipid Management
Treatment Approaches

Managing Hypertriglyceridemia

Jennifer G. Robinson, MD, MPH

Free clinical reference tool that includes treatment options; diagnosis information; guidelines; and more.

News
June 25, 2024
6 min read
Save

Q&A: Petition asks FDA to revise fenofibrate labeling to emphasize no CV outcome benefits

Q&A: Petition asks FDA to revise fenofibrate labeling to emphasize no CV outcome benefits

Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.

News
June 22, 2024
2 min read
Save

Late bedtime, insufficient sleep associated with poor cardiometabolic health

Late bedtime, insufficient sleep associated with poor cardiometabolic health

Late bedtime and too little or too much sleep were associated with higher odds for hypertension, hypertriglyceridemia and metabolic syndrome, according to a study published in Journal of the American Heart Association.

News
June 18, 2024
3 min read
Save

NLA document issued to optimize screening, management of lipids in reproductive-age women

NLA document issued to optimize screening, management of lipids in reproductive-age women

The National Lipid Association has issued a clinical consensus statement on the management of dyslipidemia in women of reproductive potential, with a focus on considerations for pharmacologic options, a speaker reported.

News
June 06, 2024
2 min read
Save

Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome

Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

News
June 06, 2024
2 min read
Save

Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome

Olezarsen safely lowers triglycerides in patients with familial chylomicronemia syndrome

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

News
June 03, 2024
3 min read
Save

Plozasiran lowers APOC3, triglycerides, other lipids in high-risk populations

Plozasiran lowers APOC3, triglycerides, other lipids in high-risk populations

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.

News
May 29, 2024
5 min read
Save

RNA interference agents appear to benefit patients with mixed hyperlipidemia

RNA interference agents appear to benefit patients with mixed hyperlipidemia

In two phase 2b trials, RNA interference agents were associated with reductions in triglycerides compared with placebo for patients with mixed hyperlipidemia.

News
May 20, 2024
2 min read
Save

To test or not to test: Isotretinoin marginally increases risk for severe adverse events

To test or not to test: Isotretinoin marginally increases risk for severe adverse events

Isotretinoin is associated with a clinically marginal increased risk for severe adverse events, leading researchers to advise routine blood testing commence shortly after initiation, according to a study.

View more